Notes on Category Selection

Original research on HIV and related infections, as well as COVID-19, monkeypox, and related urgent emerging infections are welcome to be submitted to CROI 2023 for consideration. To ensure that the best reviewers for your abstract are assigned, please make sure you submit your work to the most relevant category. All abstracts on SARS-CoV-2, monkeypox virus, and other related emerging infections, will be reviewed after the January 5, 2023, submission deadline.

Before selecting a category, please consider the following:

  • All studies of infants, children, or adolescents should be submitted to category (Q) HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents
  • All resistance studies and trials should be submitted to category (I) Resistance of HIV or SARS- CoV-2 to Small Molecules and Antibodies in Adults
  • All studies of Hepatitis (including A, B, C, D, and E in monoinfection or HIV coinfection) should be submitted to category (J) Hepatitis Viruses and Liver Complications in Adults, except that basic virology and pathogenesis of hepatitis tumor viruses should be submitted to category (C) HIV-Associated Tumor Viruses
  • Diagnostics: Studies of new technologies related to HIV drug resistance, complications, tuberculosis, other opportunistic infections, hepatitis, or malignancies should be submitted to those specific categories. Studies applying new HIV diagnostics in populations should be submitted to category (T) HIV Testing in Adults: New Diagnostics, Population Studies, and Scale-Up
  • Population and Cost Modeling: Studies that include research on demography, population impact, modeling, and cost-effectiveness should be submitted to the relevant topical category. Reviewers of these abstracts will include individuals with modeling expertise
  • Behavioral or relevant social sciences studies should be submitted to the respective categories (eg, Implementation and Scale-Up, category [Y]; Antiviral Therapy studies [H] Prevention [V or W], etc)

 

Basic Science
Category  Definition 
A  Virology of HIV, SARS-CoV-2, or Monkeypox Virus Studies related to basic HIV virology including studies of viral replication in vitro, host restriction factors, viral life cycle, entry, tropism, viral phenotypes and genotypes. Basic studies on the virology of SARS-CoV-2 and monkeypox virus are also welcome.
B  Pathogenesis of HIV, SARS-CoV-2, or Monkeypox Virus: Human Studies and Animal Models Studies of factors influencing disease outcome in humans and animal models for HIV including viral-host interactions, immune activation, host cell targets, cell compartments for infection, genotype (viral and host), and disease.  Studies addressing similar issues for SARS-CoV-2 and monkeypox virus are also welcome. 
C  HIV-Associated Tumor Viruses     Studies on basic science relating to HIV-associated tumor viruses (eg, Kaposi sarcoma-associated herpesvirus, Epstein-Barr virus, human papillomavirus, hepatitis B, Merkel cell polyomavirus) including viral life cycle, viral replication and transcription, viral-host interactions, latency, pathogenesis and oncogenesis, and viral immunology.
D  Host Immune Responses, Vaccines, and Immunotherapies: HIV, SARS-CoV-2, or Monkeypox Virus  Studies of immune responses (B-cell, T-cell, and innate) to HIV infection and vaccines, and immunomodulatory therapeutic interventions (eg, cytokine interventions, passive antibody treatment). Studies in similar areas for SARS-CoV-2 and monkeypox virus are also welcome.
E  HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy Studies of all aspects of HIV reservoirs, latency, and approaches to cure, including human and animal studies related to these topics. 
F  Neuropathogenesis and Neurologic Complications of HIV and SARS-CoV-2 Infection and Neurologic Complications of HIV in Adults Studies of all aspects of HIV neuropathogenesis including neuroimmunity, neurodegeneration, virology of central nervous system (CNS) infection, CNS complications of systemic infection (including neurocognitive dysfunction and associated factors or responses), cerebrovascular complications, and biomarkers (including neuroimaging). Similar studies related neuropathogenesis and neurologic complications of SARS-CoV-2 are welcome.
Clinical
G Clinical Pharmacology in Adults Studies of pharmacokinetics and pharmacodynamics (PK/PD) of small and large molecule drugs in animal models and adult humans, including drug absorption, distribution, metabolism, and excretion, novel dosing regimens, drug interactions, simulation and modeling, and novel uses of objective drug adherence and exposure metrics.

Studies of infants, children, or adolescents should be submitted to category (Q).
H Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 or Monkeypox Virus in Adults Studies of antiviral agents and combinations including monoclonal antibodies and new agents (all phases, including pre-clinical data, interventional trials, and observational and cohort studies) where the focus is on antiviral therapy and antiviral treatment strategies for HIV or SARS-CoV-2 or monkeypox virus including studies of patient and/or provider attitudes about different ART options, and studies of adherence.

Studies that focus on resistance should be submitted to category (I).
I Resistance of HIV or SARS- CoV-2 to Small Molecules and Antibodies in Adults Studies of molecular mechanisms, pathogenesis, clinical implications, epidemiology, and diagnostics around resistance.

Studies of infants, children, or adolescents should be submitted to category (Q).
J Hepatitis Viruses and Liver Complications in Adults Studies of diagnostics, epidemiology, pathogenesis, and therapy for hepatitis viruses and liver complications of HIV or SARS-CoV-2 in adults.

Studies of infants, children, or adolescents should be submitted to category (Q). Basic virology and pathogenesis of hepatitis tumor viruses should be submitted to (C).
K AIDS-Related Malignancies Studies of epidemiology, pathobiology, prognostic biomarkers, incidence, treatment, gynecologic malignancies, human papillomavirus screening, and prevention approaches for malignancies or premalignant lesions in patients with HIV infection.
L Cardiovascular Complications of HIV Infection and Antiretroviral Therapy Includes coronary, cardiac, and cerebrovascular complications, lipids, and peripheral vascular atheromatous disease.

Cerebrovascular complications, including stroke, should be submitted to category (F).
M Other Complications of HIV Infection and Antiretroviral Therapy in Adults Studies of renal, bone, metabolic, and other complications (excluding neurologic or liver complications) in HIV.

Neurologic complications should be submitted to category (F). Neuropathogenesis and CNS HIV Complications and liver complications should go to (J).
N Clinical Complications of Emerging Diseases (eg, COVID-19 and Monkeypox) in Adults Studies of the natural history, clinical course, co-morbidities associated with, and complications of SARS CoV-2 infection, including neurologic complications of COVID-19, in adults. Includes post-acute sequelae of COVID-19 (PASC, or long COVID) studies and the courses of acute COVID-19 disease and any lingering complications.

Neurologic complications of COVID-19 should be submitted to category (F). Studies of infants, children, or adolescents should be submitted to the categories (P) or (Q).
O Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults Basic and clinical studies of bacterial, fungal, parasitic, mycobacterial and non-hepatitis viral infections, including the impact of coinfections with SARS-CoV-2, tuberculosis and other opportunistic infections. This category will also include Integrated strategy studies that evaluate the effectiveness, safety, and acceptability of biomedical, behavioral, and structural interventions to treat or prevent coinfections and opportunistic infections in people with HIV.
P Maternal and Fetal HIV, SARS-CoV-2, Monkeypox, Virus, and Other Emerging Infections: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health Studies of maternal-fetal HIV, SARS-CoV-2 and other related infections: mother-to-child transmission; approaches to diagnosis, prevention and treatment of infections and co-morbidities during pregnancy and breast feeding; possible risks associated with treatments in pregnancy and breastfeeding; issues of postpartum maternal health; and early infant diagnosis. 
Q HIV, SARS-CoV-2, or Monkeypox Virus, and Other Emerging Infections, in Infants, Children, and Adolescents Studies of the diagnosis, treatment, and management (including biomedical, behavioral and structural interventions) of HIV and related co-infections and co-morbidities, and of SARS-CoV-2 and multisystem inflammatory syndrome in children (MIS-C), in infants, children, and adolescents, including HIV-exposed uninfected children.
Epidemiology/Public Health
R Epidemiology of HIV in Adults Studies of the incidence and prevalence of HIV. Includes risk factors for acquisition or transmission of HIV; biomedical, behavioral and structural determinants; morbidity and mortality; surveillance; transmission including phylogenetics; and molecular epidemiology; studies focused on vulnerable populations.
S Epidemiology of COVID-19, Monkeypox, and Other Emerging Infections Studies of the incidence and prevalence of SARS-CoV-2, Monkeypox, and other emerging infectious diseases. Includes risk factors for acquisition or transmission of HIV; biomedical, behavioral and structural determinants; morbidity and mortality; surveillance; transmission including phylogenetics; and molecular epidemiology; studies focused on vulnerable populations.
T HIV Testing in Adults: New Tests, Population Studies, and Scale-Up Studies evaluating the performance characteristics, implementation, and/or cost-effectiveness of HIV diagnostics and related tests. Includes clinical, community-, partner-, and self-testing; innovative approaches and technologies; scale-up of HIV-related testing; descriptive epidemiology of testing results.
U Testing for COVID-19, Monkeypox, and Other Emerging Infections: Diagnostic Tests, Population Studies, and Scale-Up Studies evaluating the performance characteristics, implementation, and/or cost-effectiveness of diagnostics and related tests for COVID-19, Monkeypox and other emerging infections of interest. Includes clinical, community-, partner-, and self-testing; innovative approaches and technologies; scale-up of testing strategies; descriptive epidemiology of testing results.
V HIV Prevention Interventions in Adults Preclinical and clinical studies of HIV prevention strategies. Includes microbicides, pre- and post-exposure prophylaxis, treatment as prevention, medical male circumcision, and other prevention interventions. Implementation of prevention strategies for HIV uninfected populations, and studies in which HIV incidence is primary outcome.

Studies of infants and children, should be submitted to category (Q); studies of pregnant and breastfeeding women should be sent to category (P).
W Prevention of COVID-19, Monkeypox, and Other Emerging Infections Preclinical and clinical studies of methods to prevent transmission of COVID-19, Monkeypox or other emerging infections. Includes PrEP, PEP, and antibodies, and other biomedical, behavioral and structural interventions.

Studies of infants and children, should be submitted to category (Q); studies of pregnant and breastfeeding women should be sent to category (P).
X Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults Studies of sexually transmitted infections, contraception and reproductive health in women and men; includes studies of contraception and other aspects of sexual and reproductive health in populations living with or at risk of HIV.

Studies on HIV epidemiology, prevention, and treatment in women and in infants, children, and adolescents should be included in their respective categories.
Y Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 and Other Emerging Infections on HIV-Related Programs Studies of HIV prevention and/or treatment cascades, implementation science studies, experiences with scale-up of HIV prevention and treatment, and population-level impact of prevention and treatment on health outcomes of persons at risk for or with HIV. Includes integrated strategy studies that evaluate the implementation of biomedical, behavioral, and structural interventions; the impact of COVID-19, Monkeypox, or other emerging infections on HIV-related services (including impacts on financing).